Supplementary material 5: Node-splitting inconsistency model

- $p < 0.05$ was set as significant inconsistency

ARI: aripiprazole, BLO: blonanserin, CLO: clozapine, Cloca: clocapramine, HAL: haloperidol, MOS: mosapramine, OLA: olanzapine, PAL: paliperidone, PER: perospirone, PBO: placebo, QUE: quetiapine, RIS: risperidone

Response rate (primary outcome)



PANSS total scores



PANSS positive subscale scores



PANSS negative subscale scores



PANSS general subscale scores



All-cause discontinuation (primary outcome)



Discontinuation due to adverse events



At least one adverse event



Agitation/anxiety/use of anxiolytics



Insomnia/use of hypnotics



Drowsiness/sedation/somnolence



Extrapyramidal symptoms/use of anticholinergic drugs/tremor



Akathisia



Increased salivation



Potentially prolactin-related adverse events



Weight change



Total cholesterol



Triglyceride